NCT02187172View on ClinicalTrials.gov

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 11, 2018

Study Completion Date

September 11, 2018

Conditions
PsoriasisCardiovascular Disease
Interventions
DRUG

Ustekinumab

DRUG

Placebo

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT02187172 - Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) | Biotech Hunter | Biotech Hunter